As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...
Two weeks before Howard Lorber retired as chairman and chief executive officer of Douglas Elliman Inc., he said at an internal inquiry that he had intimate relationships with two of the company’s ...